Potency and safety analysis of hemp-derived delta-9 products: The hemp vs. cannabis demarcation problem

Add links
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class B
  • 1-(cyclobutylmethyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide
Chemical and physical data
Molar mass347.462 g·mol−1
3D model (JSmol)
  • CC(C)(NC(=O)c3nn(CC1CCC1)c2ccccc23)c4ccccc4
  • InChI=1S/C22H25N3O/c1-22(2,17-11-4-3-5-12-17)23-21(26)20-18-13-6-7-14-19(18)25(24-20)15-16-9-8-10-16/h3-7,11-14,16H,8-10,15H2,1-2H3,(H,23,26)

CUMYL-CBMINACA (SGT-277) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug,[1] first being identified in Germany in February 2020.[2] It is illegal in Finland.[3]

See also


  1. ^ Haschimi B, Grafinger KE, Pulver B, Psychou E, Halter S, Huppertz LM, et al. (August 2021). "New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACA". Drug Testing and Analysis. 13 (8): 1499–1515. doi:10.1002/dta.3038. PMID 33788409.
  2. ^ "EU Early Warning System Situation Report. Situation report 1" (PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). June 2020.
  3. ^ "Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista" [Government Decree on psychoactive substances banned from the consumer market]. Finlex (in Finnish). Finnish Ministry of Justice.